

12th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry

&

9th Edition of International Conference on Alternative Medicine

February 26-28, 2018 London, UK

Oral administration of amphotericin B nanoparticles: Antifungal activity, bioavailability and toxicity in rats

Bushra T Al Quadeib, Mahasen A Radwan, Lidija Siller and Matthew C Wright
King Saud University, Saudi Arabia

Amphotericin B (AMB) is used most commonly in severe systemic life-threatening fungal infections. There is currently an unmet need for an efficacious (AMB) formulation amenable to oral administration with better bioavailability and lower nephrotoxicity. Novel PEGylated poly(lactic-co-glycolic acid) copolymer (PLGA-PEG) nanoparticles (NPs) formulations of AMB were therefore studied for their ability to kill *Candida albicans*. The antifungal activity of AMB formulations was assessed in *C. albicans*. Its bioavailability was investigated in nine groups of rats (n=6). Toxicity was examined by an *in vitro* blood hemolysis assay, and *in vivo* nephrotoxicity after single and multiple dosing for a week by blood urea nitrogen (BUN) and plasma creatinine (PCr) measurements. The MIC of AMB loaded to PLGA-PEG NPs against *C. albicans* was reduced two to threefold compared with free AMB. Novel oral AMB delivery loaded to PLGA-PEG NPs was markedly systemically available compared to Fungizone® in rats. The addition of 2% of GA to the AMB formulation significantly (p<0.05) improved the bioavailability from 1.5 to 10.5% and the relative bioavailability was 47.90% that of Fungizone. The novel AMB formulations showed minimal toxicity and better efficacy compared to Fungizone. No nephrotoxicity in rats was detected after a week of multiple dosing of AMB NPs based on BUN and PCr, which remained at normal levels. An oral delivery system of AMB-loaded to PLGA-PEG NPs with better efficacy and minimal toxicity was formulated. The addition of glycyrrhizic acid (GA) to AMB NPs formulation resulted in a significant oral absorption and improved bioavailability in rats.

Recent Publications

1. M A Radwana, B T Al Quadeib, N M Aloudah, H Y Aboul Enein (2010) Pharmacokinetics of ketorolac loaded to polyethylcyanoacrylate nanoparticles using UPLC MS/MS for its determination in rats. *International Journal of Pharmaceutics*. 397(1-2):173-178.
2. Mahasen A Radwan, Ghada A Bawazeer, Nouf M Aloudah, Bushra T Al Quadeib, Hassan Y Aboul-Enein (2012) Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples. *Biomed. Chromatogr*. 26(1):6-11.
3. Bushra T AL Quadeib, Mahasen A Radwan, Lidija Siller, Benjamin Horrocks, Matthew C Wright (2014) Therapeutic monitoring of amphotericin B in Saudi ICU patients using UPLC MS/MS assay. *Biomed Chromatogr*. 28(12):1652-1659.
4. Bushra T AL Quadeib, Mahasen A Radwan, Lidija Siller, Benjamin Horrocks, Matthew C Wright (2015) Stealth amphotericin b nanoparticles for oral drug delivery: *in vitro* optimization. *Saudi Pharmaceutical Journal*. 23(3):290-302.
5. Mahasen A Radwan, Bushra T Al Quadeib, Lidija Siller, Matthew C Wright, Benjamin Horrocks (2017) Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. *Drug delivery*. 24(1): 40-50.

bquadeib@ksu.edu.sa